The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment

References

• Schlieben S, Borkhardt A, Reinisch I, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): a prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia. 1996;10:957–963.
   PubMed Web of Science ®Google Scholar
• Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. Blood. 1996;87:3135–3142.
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL). Leukemia. 1995;10:1783–1786.
   Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive leukemia – results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357–2366. doi:10.1182/blood-2002-03-0704.
   PubMed Web of Science ®Google Scholar
• Rieder H, Ludwig WD, Gassmann W, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblasticleukaemia. Br J Haematol. 1996;95:678–691.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR/ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J ClinOncol. 2009;27:5202–5207. doi:10.1200/JCO.2008.21.6408.
   PubMed Web of Science ®Google Scholar
• DeBoer R, Koval G, Mulkey F, et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016;57:2298–2306. doi:10.3109/10428194.2016.1144881.
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenousleukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293.
   PubMed Web of Science ®Google Scholar
• Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93–99.
   PubMed Web of Science ®Google Scholar
• Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocyticleukaemia. Nature. 1983;306:277–280.
   PubMed Web of Science ®Google Scholar
• Chan LC, Karhi KK, Rayter SI, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature. 1987;325:635–637. doi:10.1038/325635a0.
   PubMed Web of Science ®Google Scholar
• Laurent E, Talpaz M, Kantarjian H, et al. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001;61:2343–2355.
   PubMed Web of Science ®Google Scholar
• Prywes R, Foulkes JG, Baltimore D. The minimum transforming region of v-abl is the segment encoding protein-tyrosine kinase. J Virol. 1985;54:114–122.
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–1083.
   PubMed Web of Science ®Google Scholar
• Gleissner B, Gökbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German multicenter trial group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536–1543.
   PubMed Web of Science ®Google Scholar
• Maurer J, Janssen JWG, Thiel E, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet. 1991;337:1055–1058.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995;181:307–313.
   PubMed Web of Science ®Google Scholar
• Gotoh A, Miyazawa K, Ohyashiki K, et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. ExpHematol. 1995;23:1153–1159.
   PubMed Web of Science ®Google Scholar
• Bedi A, Zehnbauer BA, Barber JP, et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994;83:2038–2044.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Zhang L, et al. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood. 2001;97:2846–2853.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8:795–806.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901–910.
   PubMed Web of Science ®Google Scholar
• Neshat MS, Raitano AB, Wang HG, et al. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and –independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000;20:1179–1186.
   PubMed Web of Science ®Google Scholar
• Sillaber C, Gesbert F, Frank DA, et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000;95:2118–2125.
   PubMed Web of Science ®Google Scholar
• Salgia R, Sattler M, Pisick E, et al. P210 BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996;24:310–313.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (ST571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493–502. doi:10.1038/nrd839.
   PubMed Web of Science ®Google Scholar
• Drucker BJ, Talpaz M, Resta D, et al. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogeneous leukemia. Blood. 1999;94(suppl.1):A1639.
   Google Scholar
• Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7. doi:10.1172/JCI9083.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–3553.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141. doi:10.1016/j.ccr.2005.01.007.
   PubMed Web of Science ®Google Scholar
• Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinibmesylate, dasatinib (BM-354825) and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332–2338. doi:10.1182/blood-2006-02-004580
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347–1348. doi:10.1093/jnci/djr292.
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66:5790–5797. doi:10.1158/0008-5472.CAN-05-4187.
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473–481. doi:10.1158/0008-5472.CAN-05-2050.
   PubMed Web of Science ®Google Scholar
• Remsing LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid cells. Leukemia. 2009;23:477–480. doi:10.1038/leu.2008.334.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potentially inhibits the T315I mutant and overcome mutation-based resistance. Cancer Cell. 2009;16:401–412. doi:10.1016/j.ccr.2009.09.028.
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahisk SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428–442. doi:10.1016/j.ccr.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Lierman E, Smits S, Cools J, et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012;26:1693–1695. doi:10.1038/leu.2012.8.
   PubMed Web of Science ®Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nature Rev Cancer. 2004;4:927–936. doi:10.1038/nrc1502.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kim DW, Rubin E, et al. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e238. doi:10.1038/bcj.2014.60.
   PubMed Web of Science ®Google Scholar
• Wylie A, Schoepfer J, Berellini G, et al. ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood. 2014;124:398.
   Web of Science ®Google Scholar
• Ottmann OG, Alimena G, DeAngelo DJ, et al. ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single-agent activity in a phase I study of patients with CML with failure of prior TKI therapy. Blood. 2015;126(23):abstract138.
   Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469–1477. doi:10.1182/blood-2005-11-4386.
   PubMed Web of Science ®Google Scholar
• Lim SN, Joo YD, Lee KH, et al. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2015;90:1013–1020. doi:10.1002/ajh.24137.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719. doi:10.1182/blood-2015-02-627935
   PubMed Web of Science ®Google Scholar
• Leis JF, Stepan DE, Curtin PT, et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma. 2004;45:695–698. doi:10.1080/10428190310001625728.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–6528. doi:10.1182/blood-2011-05-351403.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coudé MM, Huguet F, et al. Dasatinib (Sprycel®) and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWAL-Ph-01 study. Blood. 2012;120(21):666.
   Google Scholar
• Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126:746–756. doi:10.1182/blood-2015-03-636548.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796. doi:10.1056/NEJMoa1306494.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547–1555. doi:10.1016/S1470-2045(15)00207-7
   PubMed Web of Science ®Google Scholar
• Fielding AK, Goldstone AH. Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Bone Marrow Transplant. 2008;41:447–453. doi:10.1038/sj.bmt.1705904.
   PubMed Web of Science ®Google Scholar
• Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:303–306. doi:10.3324/haematol.11960.
   PubMed Web of Science ®Google Scholar
• Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009;113:2902–2905. doi:10.1182/blood-2008-10-184093.
   PubMed Web of Science ®Google Scholar
• Ram R, Storb R, Sandmaier BM, et al. Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high risk acute lymphoblastic leukemia. Haematologica. 2011;96:1113–1120. doi:10.3324/haematol.2011.040261.
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791–2793. doi:10.1182/blood-2006-04-019836.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to post-transplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106:458–463. doi:10.1182/blood-2004-05-1746.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Bethge W, et al. Up-front versus minimal residual disease triggered imatinib after stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukaemia: interim results of a randomized phase III GMALL study. Bone Marrow Transplant. 2009;43:S48.
   Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498. doi:10.1200/JCO.2010.32.7270.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Dombret H, Chevallier P, et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). Blood. 2015;126(23):679.
   Web of Science ®Google Scholar
• Gao L, Zhang C, Gao L, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicentre study in Southwest China. J Hematol Oncol. 2015;8:90. doi:10.1186/s13045-015-0186-5.
   PubMed Web of Science ®Google Scholar
• Tucunduva L, Ruggeri A, Sanz G, et al. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation. Br J Haematol. 2014;166:749–757. doi:10.1111/bjh.12970.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Gorin NC, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the acute leukaemia working party of the european group for Blood and marrow transplantation. Eur J Cancer. 2014;50:411–417. doi:10.1016/j.ejca.2013.08.027.
   PubMed Web of Science ®Google Scholar
• Böhm A, Herrmann H, Mitterbauer-Hohendanner G, et al. Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet ‘pre-leukemic’ stem cells? Leuk Lymphoma. 2011;52:842–848. doi:10.3109/10428194.2011.557168.
   PubMed Web of Science ®Google Scholar
• Giles FJ, O’Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009;23:1698–1707. doi:10.1038/leu.2009.111.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–4164. doi:10.1002/cncr.29646.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755–768. doi:10.1002/ajh.24034.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196. doi:10.1038/sj.leu.2402741.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880. doi:10.1126/science.1062538.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Barni R, Le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemia cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92:1641–1650.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology (Am Soc Hematol Educ Program). 2009;461–476. doi:10.1182/asheducation-2009.1.461.
   PubMedGoogle Scholar
• Hofmann WK, Jones LC, Lemp NA, et al. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002;99:1860–1862.
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–125.
   PubMed Web of Science ®Google Scholar
• Korashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic myeloid leukemia responding to imatinib may identify those at risk of disease progression. J Clin Oncol. 2008;26:4806–4813. doi:10.1200/JCO.2008.16.9953.
   PubMed Web of Science ®Google Scholar
• Eiring AM, Deininger MW. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol. 2014;15:461. doi:10.1186/s13059-014-0461-8.
   PubMed Web of Science ®Google Scholar
• Von Bubnoff N, Manley PW, Mestan J, et al. BCR-ABL resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the ABL kinase inhibitor nilotinib (AMN107). Blood. 2006;108:1328–1333. doi:10.1182/blood-2005-12-010132.
   PubMed Web of Science ®Google Scholar
• Boulos N, Mulder HL, Calabrese CR, et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;117:3585–3595. doi:10.1182/blood-2010-08-301267.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–3678. doi:10.1182/blood-2006-10-052746.
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110:2309–2315. doi:10.1182/blood-2007-02-073528.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol. 2003;120:145–153.
   PubMed Web of Science ®Google Scholar
• Yanada M, Sugiera I, Takeuchi J, et al. Prospective monitoring of BCR-ABL transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia undergoing imatinib-combined chemotherapy. Br J Haematol. 2008;143:503–510. doi:10.1111/j.1365-2141.2008.07377.x.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Dombret H, Schafhausen P, et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015;100:898–904. doi:10.3324/haematol.2014.115279.
   PubMed Web of Science ®Google Scholar
• Pemovska T, Johnson E, Kontro M, et al. Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation. Nature. 2015;519:102–105. doi:10.1038/nature14119.
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinibmesylate treatment. Blood. 2003;101:4701–4707. doi:10.1182/blood-2002-09-2780.
   PubMed Web of Science ®Google Scholar